The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind

Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be wrong, but investors should be able to convince themselves of that before hitting the buy button.

In the following slideshow, you'll find info on the five most shorted biotechs on the Nasdaq -- Myraid Genetics , Sarepta Therapeutics , Questcor Pharmaceuticals , Ziopharm Oncology , and MannKind -- and a brief explanation on why each company is hated so much.

A stock pick our chief investment officer loves
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


The article The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind originally appeared on Fool.com.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.